Table 1 Ongoing clinical trials in adjuvant setting

4 cycles of optional ACT followed by 2 years of TKI or placebo

• Phase III, placebo controlled; Erlotinib 150 mg/die × 2 years

• Primary endpoint: DFS

Clinician choice ACT vs Clinician choice ACT + Bevacizumab

• Phase III (2:1); Bevacizumab 15 mg/kg/3 wks

• Primary endpoint: OS

• Secondary endpoint: DFS, toxicities

CDDP DOC vs "gen assigned CT"

• Phase III (3:1) CDDP DOC/DOC/CDDP GEM vs CDDP/DOC

• Primary endpoint: DFS

• Secondary endpoint: OS, toxicities

CDDP/ERL

• Phase II feasibility

Follow up or ACT according to risk profile

• Phase II feasibility

Vaccine vs placebo after optional ACT

• Phase III (2:1) placebo controlled; separate analysis for ACT +/-

• Primary endpoint: DFS

• Secondary endpoint: OS

ACT assigned according to markers expression

• Phase III

• Primary end-point: OS

CDDP PEM vs CDDP GEM

• Randomized phase II

• Primary endpoint: feasibility

• Secondary endpoint: toxicity, delivery